Company
Incyte
Nasdaq: INCY
Wilmington, Delaware biopharmaceutical company founded in 1991. Markets Jakafi and Opzelura (ruxolitinib); now awaiting EU and US decisions on an oral JAK1 inhibitor for hidradenitis suppurativa.
1 story
Regulatory News has published 1 story about Incyte on 27 September 2026, sourced to the primary record — the regulator’s decision, the company’s filing or its own announcement. This page is generated from that coverage. Last updated 27 September 2026.
This page is generated from Regulatory News’ editorial coverage of Incyte. It is not an advertisement.
On the record
- Company
- Incyte Corporation (Nasdaq: INCY)
- Headquarters
- Wilmington, Delaware
- Founded
- 1991, as a genomics company in Palo Alto, California
- Regulator
- European Medicines Agency (CHMP)
Each line is taken from the most recent story of ours that states it.
Products in our coverage
Our coverage
